WO2005120588A3 - Peptides delivered to cell nuclei - Google Patents

Peptides delivered to cell nuclei Download PDF

Info

Publication number
WO2005120588A3
WO2005120588A3 PCT/US2005/018700 US2005018700W WO2005120588A3 WO 2005120588 A3 WO2005120588 A3 WO 2005120588A3 US 2005018700 W US2005018700 W US 2005018700W WO 2005120588 A3 WO2005120588 A3 WO 2005120588A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptides
cell nuclei
peptides delivered
useful
nuclei
Prior art date
Application number
PCT/US2005/018700
Other languages
French (fr)
Other versions
WO2005120588A2 (en
Inventor
Thomas P Quinn
Miao Yubin
Fabio Gallazzi
Original Assignee
Univ Missouri
Thomas P Quinn
Miao Yubin
Fabio Gallazzi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Missouri, Thomas P Quinn, Miao Yubin, Fabio Gallazzi filed Critical Univ Missouri
Publication of WO2005120588A2 publication Critical patent/WO2005120588A2/en
Publication of WO2005120588A3 publication Critical patent/WO2005120588A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

The present invention provides peptides that selectively target the nuclei of cells. The peptides are useful for nuclear localization of radioisotopes, therapeutics, and imaging agents. The peptides are useful for in vitro as well as in vivo applications. The present invention also provides methods of targeting and imaging cell nuclei, and methods to treat diseases using such peptides.
PCT/US2005/018700 2004-05-26 2005-05-26 Peptides delivered to cell nuclei WO2005120588A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57455804P 2004-05-26 2004-05-26
US60/574,558 2004-05-26

Publications (2)

Publication Number Publication Date
WO2005120588A2 WO2005120588A2 (en) 2005-12-22
WO2005120588A3 true WO2005120588A3 (en) 2006-04-20

Family

ID=35503675

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/018700 WO2005120588A2 (en) 2004-05-26 2005-05-26 Peptides delivered to cell nuclei

Country Status (1)

Country Link
WO (1) WO2005120588A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201903610T4 (en) 2008-05-27 2019-03-21 Genzyme Corp Peptide analogues of alpha-melanocyte stimulating hormones.
ES2364182B2 (en) 2010-02-12 2012-11-08 Universidad De Santiago De Compostela APPLICATIONS OF THE PROTEIN muNS AND ITS DERIVATIVES.
PL393529A1 (en) 2010-12-31 2012-07-02 Bioinfobank Spółka Z Ograniczoną Odpowiedzialnością Recombinant cytotoxin and process for the preparation thereof
US9290539B2 (en) 2011-05-17 2016-03-22 The Arizona Board Of Regents On Behalf Of The University Of Arizona Melanotropin ligands for skin care
WO2012158960A2 (en) 2011-05-17 2012-11-22 H. Lee Moffitt Cancer Center & Research Institute, Inc. Melanocortin 1 receptor ligands and methods of use
US20170022252A1 (en) 2014-06-10 2017-01-26 The Arizona Board Of Regents On Behalf Of The University Of Arizona Novel modulators of melanocortin receptors
US9821023B2 (en) 2014-06-10 2017-11-21 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for the treatment of central nervous system (CNS) disorders and mood disorders
US9814755B2 (en) 2014-06-10 2017-11-14 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for the treatment of depression and anxiety
US10550157B2 (en) 2015-10-16 2020-02-04 Arizona Board Of Regent On Behalf Of The University Of Arizona Compositions and methods for treating central nervous system (CNS) disorders and mood disorders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997034637A2 (en) * 1996-03-22 1997-09-25 Trustees Of Boston University Photodynamic therapy using nuclear hormone receptors to target photosensitizers

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997034637A2 (en) * 1996-03-22 1997-09-25 Trustees Of Boston University Photodynamic therapy using nuclear hormone receptors to target photosensitizers

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
EBERLE A N ET AL: "RADIOLABELED ALPHA-MELANOCYTE-STIMULATING HORMONE ANALOGS FOR RECEPTOR-MEDIATED TARGETING OF MELANOMA: FROM TRITIUM TO INDIUM", JOURNAL OF MOLECULAR RECOGNITION, HEYDEN & SON LTD., LONDON, GB, vol. 16, no. 5, September 2003 (2003-09-01), pages 248 - 254, XP008055252, ISSN: 0952-3499 *
FROIDEVAUX SYLVIE ET AL: "A gallium-labeled DOTA-alpha-melanocyte-stimulating hormone analog for PET imaging of melanoma metastases.", JOURNAL OF NUCLEAR MEDICINE, vol. 45, no. 1, January 2004 (2004-01-01), pages 116 - 123, XP002364150, ISSN: 0161-5505 *
LOBL T J ET AL: "SV40 LARGE T-ANTIGEN NUCLEAR SIGNAL ANALOGUES: SUCCESSFUL NUCLEAR TARGETING WITH BOVINE SERUM ALBUMIN BUT NOT LOW MOLECULAR WEIGHT FLUORESCENT CONJUGATES", BIOPOLYMERS, NEW YORK, NY, US, vol. 29, 1990, pages 197 - 203, XP002935519, ISSN: 0006-3525 *
ROSENKRANZ A A ET AL: "Targeted intracellular site-specific drug delivery: Photosensitizer targeting to melanoma cell nuclei.", GENETIKA, vol. 39, no. 2, February 2003 (2003-02-01), pages 259 - 268, XP009060136, ISSN: 0016-6758 *
ROSENKRANZ ANDREY A ET AL: "Recombinant modular transporters for cell-specific nuclear delivery of locally acting drugs enhance photosensitizer activity.", FASEB JOURNAL, vol. 17, no. 9, June 2003 (2003-06-01), pages 1121 - 1123 URL, XP002364149, ISSN: 0892-6638 *
SOBOLEV A S ET AL: "Approaches to targeted intracellular delivery of photosensitizers in order to enhance their efficacy and cell specificity", BIOFIZIKA, vol. 49, no. 2, March 2004 (2004-03-01), pages 351 - 379, XP009060140, ISSN: 0006-3029 *

Also Published As

Publication number Publication date
WO2005120588A2 (en) 2005-12-22

Similar Documents

Publication Publication Date Title
WO2005120588A3 (en) Peptides delivered to cell nuclei
WO2010011404A3 (en) Vectors for delivery of light-sensitive proteins and methods of use
WO2005062881A3 (en) Gene therapy using transposon-based vectors
WO2008106646A3 (en) Methods and formulations for topical gene therapy
EP3885366A3 (en) Therapeutic antibodies against ror-1 protein and methods for use of same
IL176007A0 (en) Antibodies specific to c35 and pharmaceutical compositions containing the same
WO2005113747A3 (en) Multicellular tissue and organ culture systems
GB0718957D0 (en) Optical imaging agents
WO2010081001A3 (en) Recurrent gene fusions in cancer
MX2010005830A (en) Anti-b7h4 monoclonal antibody-drug conjugate and methods of use.
WO2010129023A3 (en) Supercharged proteins for cell penetration
WO2008103920A3 (en) Targeted protein cages
WO2007044323A3 (en) Fusion proteins for blood-brain barrier delivery
WO2004074434A3 (en) Methods and compositions for administering therapeutic and diagnostic agents
MX353245B (en) METHODS FOR REPROGRAMMING CELLS and USES THEREOF.
WO2009043159A8 (en) Neural tumor stem cells and methods of use thereof
SG164368A1 (en) Treatment of cancer
MY161200A (en) Human cytomegalovirus neutralising antibodies and use thereof
WO2007061939A3 (en) Metabolite derivatives of the hdac inhibitor fk228
GB2453068A (en) Novel hepatocyte-like cells and hepatoblast-like cells derived from hbs cells
WO2007117161A1 (en) Substituted ring fused azines and their use in cancer therapy
CL2011000119A1 (en) Compounds derived from triazolo [4,3-a] pyridine; preparation procedure; pharmaceutical composition; and use in the treatment of diseases such as cancer.
WO2009155556A3 (en) Crkl targeting peptides
WO2008030818A3 (en) Novel liposome compositions
WO2007100920A3 (en) Diagnosis and treatment of prostate cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase